FDG and SGLT2 Glucose Suppression
Brief description of study
Primary objective is to:
To assess rates of complete myocardial glucose suppression (MGS) with 7 days of sotagliflozin 400 mg QD among healthy volunteers on a background of 1 day of the KD (N=20) and 3 days of the KD (N=20).
Secondary objective is to:
To investigate the relationship between sotagliflozin, targeted metabolite levels, and myocardial glucose utilization on FDG-PET. The primary outcome of this study is complete MGS, with a secondary outcome of mean SUV of the left ventricle normalized to the blood pool (myocardial-to-blood pool activity). we will also assess the association of metabolites with myocardial FDG activity on PET
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
